Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations

Cardiovascular Research Institute, University of California at San Francisco, San Francisco, Calif, USA.
The Journal of allergy and clinical immunology (Impact Factor: 11.48). 09/2009; 124(5):1099-105.e1-4. DOI: 10.1016/j.jaci.2009.07.026
Source: PubMed

ABSTRACT Mast cell tryptases have proposed roles in allergic inflammation and host defense against infection. Tryptase gene loci TPSAB1 and TPSB2 are known to be polymorphic, but the nature and extent of diversity at these loci have not been fully explored.
We sought to compare functional and nonfunctional tryptase allele frequencies and establish haplotypes in human populations.
Tryptase allele frequencies were determined by means of direct sequencing in 270 individuals from HapMap populations of European, African, Chinese, and Japanese ancestry. Haplotypes were predicted, validated in parent-child trios, and compared between populations.
We identify a new frame-shifted tryptase allele (betaIII(FS)) carried by 23% and 19% of individuals of European and African ancestry but 0% of Asian subjects. Homology models predict that betaIII(FS) is functionless. Our genotyping assay shows that allele and haplotype distributions in each population are unique. Strong linkage disequilibrium between TPSAB1 and TPSB2 (r(2)=0.83, D'=0.85) yields 2 major and 5 minor tryptase haplotypes.
Tryptase deficiency alleles (alpha and the newly discovered betaIII(FS)) are common, causing the number of inherited active genes to range from a minimum of 2 to a maximum of 4, with major differences between populations in the proportion of individuals inheriting 2 versus 4 active alleles. African and Asian populations are especially enriched in genes encoding functional and nonfunctional tryptases, respectively. Strong linkage of TPSAB1 and TPSB2 and pairing of deficiency alleles with functional alleles in observed haplotypes protect human subjects from "knockout" genomes and indeed from inheritance of fewer than 2 active alleles.

Download full-text


Available from: Bani Tamraz, Jul 01, 2014
13 Reads
  • Source
    • "Indeed, ␣-tryptase deletion was reported in 30% of a study population of 274 individuals (Soto et al., 2002), and up to 57% in a UK-based population (Abdelmotelb et al., 2013). ␣-and ␤-tryptase gene polymorphisms are numerous, and the number of functional tryptase alleles an individual may carry varies from two to four (Trivedi et al., 2009). Although it seems that complete tryptase deficiency is not seen in human populations, the number and type of functional alleles carried by an individual may alter the baseline systemic tryptase levels. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The most abundant prestored enzyme of human mast cell secretory granules is the serine-protease tryptase. In humans, there are four tryptase isoforms, but only two of them, namely the alpha and beta tryptases, are known as medically important. Low levels of continuous tryptase production as an immature monomer makes up the major part of the baseline serum tryptase levels, while transient release of mature tetrameric tryptase upon mast cell degranulation accounts for the anaphylactic rise of serum tryptase levels. Serum tryptase determination contributes to the diagnosis or monitoring of mast cell disorders including mast cell activation - induced anaphylaxis, mastocytosis and a number of myeloproliferative conditions with mast cell lineage involvement. Baseline serum tryptase levels are predictive of the severity risk in some allergic conditions.
    Molecular Immunology 05/2014; 63(1). DOI:10.1016/j.molimm.2014.04.001 · 2.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review summarizes selected articles appearing in 2008 in the Journal. Articles chosen include those improving our understanding of mechanisms of allergic diseases by focusing on human basophil, mast cell, and eosinophil biology; IgE and its high-affinity receptor on various cells; novel properties of omalizumab; airways remodeling; and genetics. Articles from other journals have been included to supplement the topics presented.
    The Journal of allergy and clinical immunology 04/2009; 123(3):569-74. DOI:10.1016/j.jaci.2009.01.041 · 11.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mast cells make and secrete an abundance of peptidases, which are stored in such large amounts in granules that they comprise a high fraction of all cellular protein. Perhaps no other immune cell is so generously endowed with peptidases. For many years after the main peptidases were first described, they were best known as markers of degranulation, for they are released locally in response to mast cell stimulation and can be distributed systemically and detected in blood. The principal peptidases are tryptases, chymases, carboxypeptidase A3, and dipeptidylpeptidase I (cathepsin C). Numerous studies suggest that these enzymes are important and even critical for host defense and homeostasis. Endogenous and allergen or pathogen-associated targets have been identified. Belying the narrow notion of peptidases as proinflammatory, several of the peptidases limit inflammation and toxicity of endogenous peptides and venoms. The peptidases are interdependent, so that absence or inactivity of one enzyme can alter levels and activity of others. Mammalian mast cell peptidases--chymases and tryptases especially--vary remarkably in number, expression, biophysical properties, and specificity, perhaps because they hyper-evolved under pressure from the very pathogens they help to repel. Tryptase and chymase involvement in some pathologies stimulated development of therapeutic inhibitors for use in asthma, lung fibrosis, pulmonary hypertension, ulcerative colitis, and cardiovascular diseases. While animal studies support the potential for mast cell peptidase inhibitors to mitigate certain diseases, other studies, as in mice lacking selected peptidases, predict roles in defense against bacteria and parasites and that systemic inactivation may impair host defense.
    American Journal of Respiratory Cell and Molecular Biology 11/2009; 42(3):257-67. DOI:10.1165/rcmb.2009-0324RT · 3.99 Impact Factor
Show more